Transkaryotic files IND for Hunter syndrome

TKTX filed an IND to begin a 12-patient, dose-escalating, placebo-controlled Phase I/II study of its iduronate-2-sulfatase ( I2S) enzyme replacement therapy to treat Hunter syndrome. The genetic disor...